Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324450 | 0.84 | KMT2A (0.59) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL27602299 | 0.81 | GAA (0.59) | KMT2AMEN1KDM4EEGFRERBB2 | |
| SCHEMBL5089606 | 0.80 | ALDH1A1 (0.61) | KMT2AMEN1KDM4ELMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27604835 | 0.78 | ALDH1A1 (0.59) | KMT2AMEN1L3MBTL1KDM4EHTT | |
| SCHEMBL4764012 | 0.77 | KMT2A (0.65) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL1431992 | 0.76 | ALDH1A1 (0.50) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL12941833 | 0.76 | AOC2 (0.56) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL21665925 | 0.76 | KMT2A (0.54) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL5871721 | 0.76 | KMT2A (0.69) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL30034756 | 0.74 | MEN1 (0.83) | KMT2AMEN1HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812165-B2 | 6-substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| EP-1742947-B1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1742947-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108398-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | PNPO, CYP2D6, DPYD | KMT2A 3979/4885MEN1 1188/4885L3MBTL1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.